United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported indirect gifts of company stock held through family trusts. The filing shows two bona fide gifts of Common Stock totaling 11,069 shares, made at a price of $0.00 per share.
After these gifts, one reporting trust holds 8,902 shares of United Therapeutics Common Stock and another trust holds 249,108 shares, both reported as indirect ownership. Additional indirect holdings disclosed include 45,596 shares and 324,443 shares held by family trusts, and 166 shares held by a spouse. These are non-market, gratuitous transfers and not open-market sales.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On May 22, 2026, she exercised stock options for 9,500 shares of common stock at $146.03 per share and sold 9,500 shares in open-market trades at prices around $563–$570 per share.
The filing states these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which remains in effect until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. After the transactions, she held 40,513 shares of common stock directly, plus additional indirect holdings through various family trusts and a small position held by her spouse.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond reported a series of insider transactions in the company’s common stock. On May 21, 2026, he exercised 10,000 stock options at an exercise price of $117.76 per share, converting them into common shares.
That same day, he executed multiple open-market sales totaling 10,000 shares at prices in the mid‑$560s, with trades reported at weighted average prices such as $566.12 and $563.12. The filing states these transactions were carried out under a Rule 10b5‑1 trading plan entered into on October 31, 2025, indicating they were pre‑scheduled.
After these transactions, Edgemond directly owns 18,876 shares of United Therapeutics common stock and holds 70,000 stock options following the 10,000‑share option exercise.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported option exercises and related share sales in United Therapeutics common stock. On 2026-05-21, she exercised 9,500 stock options at an exercise price of $146.03 per share, receiving an equal number of common shares.
That same day, she sold 9,500 common shares in multiple open-market transactions at weighted average prices generally between about $560 and $566, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she directly held 40,513 common shares and also had additional indirect holdings through various family trusts and a spouse account.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported an option exercise and related share sales. On May 20, 2026, she exercised stock options for 9,500 shares of common stock at a strike price of $146.03 per share and sold 9,500 shares in multiple open-market transactions at prices generally in the $561–$578 range.
These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 stock options expiring on March 17, 2027, or December 31, 2026. Following the transactions, she directly holds 40,513 common shares and also has indirect holdings through several family trusts and a spouse account.
UNITED THERAPEUTICS Corp executive Paul A. Mahon exercised stock options and sold shares of Common Stock in pre-planned trades. On May 21, 2026, the EVP & General Counsel exercised options covering 8,300 shares at a conversion price of $146.03 per share and sold 8,300 shares in multiple open-market transactions at weighted-average prices in the mid-$560s. These trades were executed pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025. After the transactions, Mahon directly holds 45,172 shares of UNITED THERAPEUTICS Common Stock.
UTHR affiliate files a Form 144 proposing the sale of 8,300 shares of Common Stock via a stock option exercise on 05/21/2026. The filing also lists five completed sales of 8,300 shares each on 05/07/2026, 04/16/2026, 04/02/2026, 03/19/2026, and 03/05/2026 with reported proceeds of $4,870,054.05, $4,787,596.87, $4,696,690.29, $4,398,610.73, and $4,010,187.33, respectively.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an option exercise and related share sales. On May 19, 2026, she exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and sold 9,500 shares in multiple open-market transactions at weighted average prices generally around $561–$572 per share. The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 options expiring on March 17, 2027 or December 31, 2026. Rothblatt also reports indirect ownership of additional common shares through various family trusts and her spouse.
United Therapeutics CFO and Treasurer James Edgemond reported a combination of stock option exercises and share sales in the company’s common stock. On May 18, 2026, he exercised options for 10,000 shares at strike prices of $117.76 and $135.42 per share, then sold 10,000 shares in multiple open-market transactions at prices between approximately $562.91 and $570.18. The filing states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025, and he continues to hold United Therapeutics common stock following the activity.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported a combination of stock option exercise and pre-planned share sales. She exercised stock options covering 9,500 shares of common stock at a $146.03 exercise price and sold 9,500 shares in multiple open-market trades at weighted average prices around $565–$570 per share. These transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which allows up to the exercise of 1,734,410 stock options expiring on March 17, 2027, or runs until December 31, 2026, whichever occurs first. Following the reported transactions, she directly holds 40,513 shares of common stock, in addition to indirect holdings through family trusts and her spouse.